Lobe Sciences Ltd.

Recent News

  • Lobe Sciences Announces Incorporation of Australian Subsidiary

    Vancouver, British Columbia--(Newsfile Corp. - September 23, 2022) -  Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has incorporated Lobe Sciences Australia Pty Ltd., a 100% owned Australian subsidiary of the Company, to facilitate the three or more clinical trials in Australia with newly announced partner iNGENū Pty Ltd. The trials aim to evaluate Lobe's proprietary psilocin...

    2022-09-23 8:00 AM EDT
  • Lobe Sciences Announces Closing of Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease, today announced that it has closed a non-brokered private placement of units (the "Units") for gross proceeds of $1,347,500 (the "Offering"). "We are extremely pleased to close this financing and are thankful for the support and confidence of our investors who join...

    2022-09-08 2:55 PM EDT
  • Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia

    Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible note financing bearing interest at 15% per annum with a term of 12 months (the "Convertible Notes") with Cantheon Capital ("Cantheon") for aggregate proceeds to the Company of up to USD$1,500,000 to...

    2022-09-01 9:21 AM EDT
  • Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans

    Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other initiatives, describes its plans for advancing the development of its psilocin analogues L-130 and L-131.Philip Young, CEO of Lobe Sciences stated, "We have made significant progress toward initiating our first human...

    2022-08-19 9:24 AM EDT
  • Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

    Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd. ("iNGENū"), an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131.Philip Young, CEO of Lobe Sciences...

    2022-08-10 9:16 AM EDT
  • Lobe Sciences Files Patent Application Covering the Preparation of Stable Psilocin Prodrugs and Analogues and their Uses Further Strengthening its Intellectual Property Portfolio

    Vancouver, British Columbia--(Newsfile Corp. - July 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has filed a provisional patent for the preparation and use of its proprietary and stable psilocin related compounds.Philip Young, CEO of Lobe Sciences stated, "Our patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin,...

    2022-07-19 7:48 AM EDT
  • Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023

    Vancouver, British Columbia--(Newsfile Corp. - July 7, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biotechnology company committed to discovering and developing psychedelic derived medicines today announced it has developed its initial Phase 1 study plan intended to demonstrate the safety and appropriate dosing range for its proprietary new chemical entity; L-130. It is also announcing the acquisition of a second new chemical entity, L-131, which is expected to enter preclinical toxicity trials...

    2022-07-07 10:22 AM EDT
  • Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.'s Global Regulatory and Development Strategy and its Implementation

    Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with Clearway Global LLC ("Clearway"). Philip Young, CEO of Lobe stated, "We are pleased to have the opportunity to team up with the Clearway network and in particular with Dr. Fred Sancilio,...

    2022-06-21 9:15 AM EDT